SCHEMBL18170635

SCHEMBL18170635

CSc1cccc(NC(=O)Nc2ccc(-c3ccccc3)c3c2C(=O)NC3)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.64
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ROCK2 O75116 3/20 0.52
RET P07949 3/20 0.52
AURKB Q96GD4 3/20 0.52
FLT1 P17948 2/20 0.52
EPHA2 P29317 2/20 0.52
FLT4 P35916 2/20 0.52
FLT3 P36888 2/20 0.52
AXL P30530 1/20 0.52
FRK P42685 1/20 0.52
MAP4K4 O95819 2/20 0.52
LCK P06239 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170775 0.86 KDR (0.68) KDRROCK2RETAURKBFLT1
SCHEMBL18170522 0.85 KDR (0.62) KDRROCK2RETAURKBFLT1
SCHEMBL18170877 0.85 KDR (0.66) KDRROCK2RETAURKBFLT1
SCHEMBL18170921 0.81 KDR (0.71) KDRROCK2RETAURKBFLT1
SCHEMBL18170710 0.80 KDR (0.60) KDRMEN1KMT2A
SCHEMBL18170946 0.80 KDR (0.66) KDRMAPTSMN1; SMN2ROCK2RET
SCHEMBL3840842 0.80 KDR (0.71) KDRROCK2RETAURKBFLT1
SCHEMBL18170997 0.79 KDR (0.65) KDRROCK2RETAURKBFLT1
SCHEMBL18170670 0.79 KDR (0.62) KDRROCK2RETAURKBFLT1
SCHEMBL18170484 0.79 KDR (0.62) KDRROCK2RETAURKBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US claimed
US-9856216-B2 Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same GREEN CROSS CORPORATION (KR) 2018-01-02 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311772-A1 COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME TNIK, TNK1, NFKBIA KDR 1662/4885MEN1 1064/4885KMT2A 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.